Entrada Therapeutics (TRDA) Cash from Investing Activities (2020 - 2026)

Entrada Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 464.23% year-over-year to $27.0 million in Q1 2026; TTM through Mar 2026 was $139.0 million, a 382.76% increase from a year earlier, with the FY2025 full-year figure at $116.8 million, up 520.2% from the prior year.
• Cash from Investing Activities retreated to $27.0 million in Q1 2026 per TRDA's latest filing, from $29.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $53.4 million in Q4 2024 and bottomed at -$181.5 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $18.8 million (2022), against an average of -$10.1 million.
• Biggest YoY gain for Cash from Investing Activities was 1668.98% in 2022; the steepest drop was 19892.62% in 2022.
• Year by year, Cash from Investing Activities stood at $18.8 million in 2022, then rose by 1.34% to $19.0 million in 2023, then surged by 180.23% to $53.4 million in 2024, then tumbled by 45.43% to $29.1 million in 2025, then slipped by 7.32% to $27.0 million in 2026.
• Per Business Quant, the three latest TRDA Cash from Investing Activities figures stand at $27.0 million (Q1 2026), $29.1 million (Q4 2025), and $49.1 million (Q3 2025).